Tolvaptan (JINARC®) RISK MANAGEMENT PROGRAM PRESCRIBER GUIDE

JINARC® BOXED WARNING*: Tolvaptan (JINARC®) can cause serious and potentially fatal liver injury, including acute liver failure requiring transplantation. To reduce this risk, ALT, AST, and bilirubin levels should be measured before starting treatment, monthly for the first 18 months and every 3 months after that. If laboratory abnormalities or signs of liver injury occur, prompt action can help reduce but not eliminate the risk of liver damage. Due to the risks, JINARC® is only available through a restricted distribution program called JINARC® RMP.

DEFINITION OF SERIOUS AND POTENTIALLY FATAL LIVER INJURY*

Report any of the following liver injury events as serious and potentially fatal:

- **Development of any liver injury leading to liver transplantation or resulting to any fatal/life-threatening outcome.**
- **Development of any liver injury events meeting any of the laboratory criteria presented below:**
  - **ALT or AST levels greater than 8 times the ULN (Upper Limit of Normal)**
  - **ALT or AST levels greater than 5 times the ULN for more than two weeks**
  - **ALT or AST levels greater than 3 times the ULN and BT levels greater than 2 times the ULN or INR (International Normalized Ratio) levels greater than 1.5 (BT levels can be measured within 30 days of the ALT elevation) or**
  - **ALT or AST levels greater than 3 times the ULN and the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)**

WHAT IS THE JINARC® RMP?

The JINARC® RMP is a strategy required by Otsuka to manage the risk of serious liver injury associated with the use of JINARC®. JINARC® can cause serious liver injury, so regular monitoring and liver enzyme (ALT, AST, BT) testing is required before and during treatment. Prompt recognition and response to symptoms can help reduce the risk of more serious liver injury. To ensure safe use, JINARC® is only available through the JINARC® RMP, a restricted distribution program.

WHAT ARE THE REQUIREMENTS OF JINARC® RMP?

To prescribe JINARC®, healthcare providers need to follow these steps:

1. **Complete a one-time certification process.**
2. **Counsel patients and conduct baseline liver enzyme (ALT, AST, BT) testing before enrolling them in the RMP and writing a prescription.**
3. **Continuously monitor patients, conduct liver enzyme (ALT, AST, BT) testing on the 2nd and 4th week of the 1st month, monthly from 2nd to 18th month, and every 3 months thereafter.**

HOW DOES A PRESCRIBER BECOME CERTIFIED?

To prescribe JINARC® safely, follow these steps:

1. **Read the educational materials on JINARC® found on the website to understand the risk of severe and potentially fatal liver injury, which includes the Prescribing Information and Prescriber Guide.**
2. **Pass the Jinarc® Risk Management Assessment. Once you pass, the JINARC® RMP will send a notification of your certification to your email.**

HOW DO I ENROLL A PATIENT IN THE JINARC® RMP?

To enroll a patient in the JINARC® RMP:

1. **Counsel the patient on the risks and monitoring requirements [before the first dose, on the 2nd and 4th week of the first month, monthly from the 2nd to 18th month, and every 3 months thereafter] using the Patient Guide.**
2. **Order and evaluate liver function test (LFT such AST, ALT, BT) before writing the prescription.**
3. **Once qualified, inform the patient to contact JINARC® Patient Support Team.**

ONCE A PATIENT IS ON JINARC®, HOW OFTEN SHOULD I MONITOR PATIENTS?

1. **Order and review liver laboratory tests (liver transaminases and total bilirubin) at specific time points after treatment initiation, as follows:**
    - **On the 2nd and 4th week of the 1st month**
    - **Monthly from the 2nd to 18th month**
    - **Every 3 months thereafter**
2. **Assess the patient's liver function and determine the appropriateness of continuing treatment.**

HOW SHOULD I REPORT LIVER ADVERSE EVENTS?

- **Healthcare providers must notify the OPPI-Pharmacovigilance of any adverse events, adverse drug reactions or patient safety concerns.**

- **Call or email us using the following contact information:**
    - **Email: oppi-pv@otsuka.com.ph**
    - **Mobile: +63999 886 9910**
    - **Phone: +632 8844 9266, +632 8888 6774**
    - **Fax: +63999 886 9910**

***For Full Prescribing Information, please see Tolvaptan (JINARC®) package Insert*. Reference:**

Tolvaptan (JINARC®) [Package Insert]. Tokushima, Japan; OPC; December. 2022.

Otsuka

Otsuka (Philippines) Pharmaceutical, Inc.

Manufactured by Otsuka Pharmaceutical Co., Ltd. Tokushima, 779-0195, Japan.
Distributed and marketed by Otsuka (Philippines) Pharmaceutical, Inc., 3rd Floor, Kings Court II Building, 2129 Chino Roces Avenue, Makati City 1231, Philippines.
 May 2023 **JIN-2023-04-04**